CYCN
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Cyclerion Therapeutics, Inc. (CYCN) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Profitability (C-). The rating has held at C+ for 10 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B- (3.0) | C+ (2.5) | C- (2.1) | C+ (2.5) | C+ (2.6) | C+ (2.5) |
| 2026-11-04 | B- (3.0) | C+ (2.5) | C- (2.1) | C+ (2.5) | C+ (2.7) | C+ (2.6) |
| 2026-10-28 | B- (3.0) | C+ (2.5) | C- (2.1) | C+ (2.5) | C+ (2.7) | C+ (2.6) |
| 2026-10-21 | B- (3.0) | C+ (2.5) | C- (2.1) | C+ (2.5) | C+ (2.6) | C+ (2.5) |
| 2026-10-14 | B- (3.0) | C+ (2.5) | C- (2.1) | C+ (2.5) | C+ (2.6) | C+ (2.5) |